• Annals of Clinical Neurophysiology
• /
• 제6권2호
• /
• pp.92-97
• /
• 2004

Background: There were several studies comparing prognostic factors in Guillain-Barre syndrome treated with intravenous immunoglobulin and plasmapheresis. However, there were controversies in what were significant factors and there were few studies so far comparing the therapeutic outcomes in patients treated with immunoglobulin. This study was aimed to determine the prognostic factors which affected the therapeutic outcome of Guillain-Barre syndrome treated with intravenous immunoglobulin. Method: We retrospectively reviewed the medical records of patients with Guillain-Barre syndrome admitted to our hospital between January 1999 and March 2004. All patients were treated with intravenous immunoglobulin. Outcome and prognosis were followed up after four weeks using the overall disability sum score. Results: Thirty-six patients were enrolled in this study. According to the clinical and electrophysiological findings, 17 patients were AIDP, 10 were axonal forms, two were mixed and seven had electrophysiologically no evidence of abnormalities. At a follow-up of four weeks, disabilities at the nadir (p<0.001) and admission (P<0.012), initial manifestations of bulbar symptom (P<0.024) and electrodiagnostic features (P<0.013) were significantly correlated with outcome in patients treated with intravenous immunoglobulin. But only disabilities at the nadir (P<0.033) and electrodiagnostic features (P<0.018) were significant in the multivariate logistic regression analysis. Conclusion: Among the patient treated with intravenous immunoglobulin, the outcomes were significantly different according to the neurological status at the nadir. Therefore early diagnosis, administration of intravenous immunoglobulin and preventing complications during acute stages are essential to minimize neurological deficit and shorten the periods of recovery.

• Clinical and Experimental Pediatrics
• /
• 제62권4호
• /
• pp.119-123
• /
• 2019

Kawasaki disease (KD) is a systemic vasculitis that mainly affects younger children. Intravenous immunoglobulin (IVIG) resistant cases are at increasing risk for coronary artery complications. The strategy on prediction of potential nonresponders and treatment of IVIG-resistant patients is now controversial. In this review the definition and predictors of IVIG-resistant KD and current evidence to guide management are discussed.

• Pediatric Infection and Vaccine
• /
• 제21권1호
• /
• pp.29-36
• /
• 2014

목적: 이 연구의 목적은 면역글로불린-저항성 가와사키병의 예측 인자를 찾고 점수화된 예측 모델을 만들고자 하는 것이다. 방법: 2009년 1월부터 2012년 12월까지 세브란스 어린이 병원에서 가와사키병으로 진단된 573명의 환자를 대상으로 하였다. 실험군과 검증군으로 나누었고, 각 군들은 면역글로불린-반응성과 저항성으로 나누었다. 실험군에서 면역글로불린의 예측 인자를 찾았고, 점수화된 예측모델을 만들었다. 그리고 외적, 내적 타당성 검증을 시행하였다. 결과: 남성, 경부림프절종대, 손과 발의 변화, 혈소판, 총빌리루빈, 젖산탈수효소, CRP가 면역글로불린-저항성 가와사키병의 예측 인자로 나타났다. 점수화된 예측 모델을 만들었고, 민감도와 특이도가 실험군에서는 52.5%와 82.4%, 검증군에서는 37.8%와 81.8%로 나타났다. 결론: 우리의 점수화된 예측 모델은 한국 환자에 적용하였을 때 높은 특이도와 낮은 민감도를 갖는다.

• Journal of Yeungnam Medical Science
• /
• 제18권2호
• /
• pp.246-252
• /
• 2001

고용량 스테로이드 충격 요법에 반응하지 않는 심한 복통과 신생검에서 50% 이상 반월체 형성이 되는 알레르기성 자반증 산염 환자의 치료를 위하여 고용량 정맥용 면역 글로불린을 투여하여 복부 증상이 조기 회복되었으며 이후 혈뇨와 단백뇨도 호전되었다. 그러므로 복부 증상과 선장 침범이 스테로이드 치료야 반응하지 않는 알레르기성 자반증 환자의 경우에 정맥용 면역 글로블린 치료가 고려되어야 할 것으로 사료된다.

• Annals of Clinical Neurophysiology
• /
• 제14권1호
• /
• pp.49-51
• /
• 2012

• Childhood Kidney Diseases
• /
• 제12권2호
• /
• pp.233-238
• /
• 2008

거대 세포 바이러스가 IgA 신병증과 연관되었다는 설은 예로부터 논쟁거리가 되어 왔다. 일반적으로 ganciclovir는 거대세포바이러스의 치료제로 알려져 있으나, 부작용 및 독성 때문에 정상 면역을 가진 소아 환자들에게서는 잘 쓰이지 않는다. 본 저자들은 거대세포바이러스와 연관되었다고 생각되는 중증 IgA 신병증 환아를 deflazacort와 정맥 면역글로불린을 병용 투여하여 호전된 경우를 경험하여 보고하는 바이다.

• 한국임상수의학회지
• /
• 제30권1호
• /
• pp.61-65
• /
• 2013

An American Cocker Spaniel (3-year-old, intact female, 6.0 kg) was referred to the Veterinary Medical Teaching Hospital of Chungnam National University for evaluation of pustules and crusts in the periocular region, dorsal and ventral region of the trunk, and digits. Complete blood count (CBC) revealed leukocytosis with mature neutrophilia, and a serum biochemistry profile revealed hypoalbuminemia. Tape strip tests identified numerous neutrophils and acatholytic cells. Histopathology identified intraepithelial pustules with neutrophils and acantholytic keratinocytes. Definitive diagnosis of pemphigus foliaceus (PF) was made by direct immunofluorescence (DIF) test with goat anti-canine IgG antibody. The human intravenous immunoglobulin (IVIG) was administered at a rate of 15 ml/h over 6 hours for 4 days. After that, the dog was maintained on prednisolone (2.2 mg/kg, PO, SID) and azathioprine (2.0 m/kg, PO, SID). An infusion of IVIG (0.5 g/kg) was repeated 3 days after 4 weeks. After 10 weeks, the dog showed the remarkable regression of lesions.

• Annals of Clinical Neurophysiology
• /
• 제8권1호
• /
• pp.6-15
• /
• 2006

Intravenous immunoglobulin (IVIg) is the treatment of choice for many autoimmune neuropathic disorders such as Guillain-Barre syndrome (GBS), chronic inflammatory Demyelinating neuropathy (CIDP), and multifocal motor neuropathy (MMN). IVIg is preferred because the adverse reactions are milder and fewer than the other immune-modulating methods such as steroid, other immunosuppressant such as azathioprine, and plasmapheresis. IVIg also has been used in other autoimmune neuromuscular disorders (inflammatory myopathy, myasthenia gravis, and Lambert-Eaton myasthenic syndrome) and has been known as safe and efficient agent in these disorders. Since IVIg would get more indications and be used more commonly, clinicians need to know the detailed mechanism of action, side effects, and practical points of IVIg.

• Annals of Clinical Neurophysiology
• /
• 제8권1호
• /
• pp.48-52
• /
• 2006

Background: Intravenous immunoglobulin (IVIg) has been administered for various immune-mediated neurological diseases such as autoimmune neuropathy, inflammatory myopathies, and other autoimmune neuromuscular disorders. The purpose of this study is to investigate side effects and complications of IVIg therapy in neuromuscular disorders. Methods: We enrolled 29 patients (age 8~63 years) with IVIg therapy for various neurological diseases including Guillain-Barre syndrome, myasthenia gravis, dermatomyositis, polymyositis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. IVIg therapy was used at a dose of 0.4 g/kg body weight/day for 5 consecutive days. Results: 10 patients (34%) had adverse events. There are adverse events in 16 courses (11%) among total 145 courses. The majority of patients presented with mild side effects, mostly asymptomatic laboratory changes. Rash or mild headache occurred in 3 patients. One patient showed a serious side effect of deep vein thrombosis. Conclusions: IVIg therapy is safe for a variety of immune-mediated neurological diseases in our study.

• Annals of Clinical Neurophysiology
• /
• 제18권1호
• /
• pp.14-17
• /
• 2016

Intravenous immunoglobulin (IVIG) is a safe treatment to treat various neurological disorders, but fatal thrombotic events as rare complications have been reported. A 54-year-old woman with Guillain-Barre syndrome complained of dyspnea during IVIG treatment. She was finally diagnosed with pulmonary thromboembolism. To the best of our knowledge, this is the first case of pulmonary thromboembolism associated with IVIG treatment in a Korean patient with Guillain-Barre syndrome.